These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33972247)

  • 1. Pseudomonas aeruginosa Ventilator-Associated Pneumonia Rabbit Model for Preclinical Drug Development.
    Nguyen NTQ; Gras E; Tran ND; Nguyen NNY; Lam HTH; Weiss WJ; Doan TNM; Diep BA
    Antimicrob Agents Chemother; 2021 Jun; 65(7):e0272420. PubMed ID: 33972247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antivirulence Bispecific Monoclonal Antibody-Mediated Protection against Pseudomonas aeruginosa Ventilator-Associated Pneumonia in a Rabbit Model.
    Aguiar-Alves F; Le HN; Tran VG; Gras E; Vu TTT; Dong OX; Quetz JS; Cheng LI; Yu L; Sellman BR; Stover CK; DiGiandomenico A; Diep BA
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0202221. PubMed ID: 34902264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aerosolized tobramycin for Pseudomonas aeruginosa ventilator-associated pneumonia in patients with acute respiratory distress syndrome.
    Migiyama Y; Hirosako S; Tokunaga K; Migiyama E; Tashiro T; Sagishima K; Kamohara H; Kinoshita Y; Kohrogi H
    Pulm Pharmacol Ther; 2017 Aug; 45():142-147. PubMed ID: 28450200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Combination Antibiogram Evaluation for
    Puzniak L; DePestel DD; Srinivasan A; Ye G; Murray J; Merchant S; DeRyke CA; Gupta V
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30917987
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of the duration of antibiotics on clinical events in patients with Pseudomonas aeruginosa ventilator-associated pneumonia: study protocol for a randomized controlled study.
    Bouglé A; Foucrier A; Dupont H; Montravers P; Ouattara A; Kalfon P; Squara P; Simon T; Amour J;
    Trials; 2017 Jan; 18(1):37. PubMed ID: 28114979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nebulized Amikacin and Fosfomycin for Severe Pseudomonas aeruginosa Pneumonia: An Experimental Study.
    Li Bassi G; Motos A; Fernandez-Barat L; Aguilera Xiol E; Chiurazzi C; Senussi T; Saco MA; Fuster C; Carbonara M; Bobi J; Amaro R; De Rosa F; Comaru T; Yang H; Ranzani OT; Marti JD; Rinaudo M; Comino Trinidad O; Rigol M; Bringué J; Ramirez J; Nicolau DP; Pelosi P; Antonelli M; Blasi F; Artigas A; Montgomery AB; Torres A
    Crit Care Med; 2019 Jun; 47(6):e470-e477. PubMed ID: 30882478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015-2018.
    Pfaller MA; Shortridge D; Harris KA; Garrison MW; DeRyke CA; DePestel DD; Moise PA; Sader HS
    Int J Infect Dis; 2021 Nov; 112():321-326. PubMed ID: 34597763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of doripenem versus meropenem for hospital-acquired and ventilator-associated pneumonia.
    Liu WD; Shih MC; Chuang YC; Wang JT; Sheng WH
    J Microbiol Immunol Infect; 2019 Oct; 52(5):788-795. PubMed ID: 31155463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo efficacy of biapenem with ME1071, a novel metallo-β-lactamase (MBL) inhibitor, in a murine model mimicking ventilator-associated pneumonia caused by MBL-producing Pseudomonas aeruginosa.
    Yamada K; Yanagihara K; Kaku N; Harada Y; Migiyama Y; Nagaoka K; Morinaga Y; Nakamura S; Imamura Y; Miyazaki T; Izumikawa K; Kakeya H; Hasegawa H; Yasuoka A; Kohno S
    Int J Antimicrob Agents; 2013 Sep; 42(3):238-43. PubMed ID: 23891525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem.
    Secher T; Fas S; Fauconnier L; Mathieu M; Rutschi O; Ryffel B; Rudolf M
    PLoS One; 2013; 8(9):e73396. PubMed ID: 24023870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics.
    Chen M; Buurma V; Shah M; Fahim G
    Am J Health Syst Pharm; 2019 Sep; 76(18):1383-1394. PubMed ID: 31505562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia.
    Luyt CE; Aubry A; Lu Q; Micaelo M; Bréchot N; Brossier F; Brisson H; Rouby JJ; Trouillet JL; Combes A; Jarlier V; Chastre J
    Antimicrob Agents Chemother; 2014; 58(3):1372-80. PubMed ID: 24342638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interpreting carbapenem susceptibility testing results for Pseudomonas aeruginosa.
    Micaëlo M; Brossier F; Bréchot N; Luyt CE; Lu Q; Monsel A; Jarlier V; Aubry A
    Med Mal Infect; 2018 Aug; 48(5):365-371. PubMed ID: 29628176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia.
    Lodise TP; Sorgel F; Melnick D; Mason B; Kinzig M; Drusano GL
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1606-10. PubMed ID: 21300830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful Intratracheal Treatment of Phage and Antibiotic Combination Therapy of a Multi-Drug Resistant
    Duplessis C; Warawa JM; Lawrenz MB; Henry M; Biswas B
    Antibiotics (Basel); 2021 Aug; 10(8):. PubMed ID: 34438996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEDI3902 Correlates of Protection against Severe Pseudomonas aeruginosa Pneumonia in a Rabbit Acute Pneumonia Model.
    Le HN; Quetz JS; Tran VG; Le VTM; Aguiar-Alves F; Pinheiro MG; Cheng L; Yu L; Sellman BR; Stover CK; DiGiandomenico A; Diep BA
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29483116
    [No Abstract]   [Full Text] [Related]  

  • 17. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.
    Torres A; Zhong N; Pachl J; Timsit JF; Kollef M; Chen Z; Song J; Taylor D; Laud PJ; Stone GG; Chow JW
    Lancet Infect Dis; 2018 Mar; 18(3):285-295. PubMed ID: 29254862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of combination therapy and early de-escalation on outcome of ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
    Deconinck L; Meybeck A; Patoz P; Van Grunderbeeck N; Boussekey N; Chiche A; Delannoy PY; Georges H; Leroy O
    Infect Dis (Lond); 2017 May; 49(5):396-404. PubMed ID: 28092204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia.
    Louie A; Liu W; Fikes S; Brown D; Drusano GL
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2788-92. PubMed ID: 23571540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance.
    Fernández-Barat L; Ferrer M; De Rosa F; Gabarrús A; Esperatti M; Terraneo S; Rinaudo M; Li Bassi G; Torres A
    J Infect; 2017 Feb; 74(2):142-152. PubMed ID: 27865895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.